drugset / Trial / NCT05992077
Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
Active not recruiting
21000 enrolled
ANRS, Emerging Infectious Diseases
Institute Pasteur, Cambodia · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the effectiveness of sofosbuvir/daclatasvir combination for children aged ≥ 6 years old and adolescents with active HCV infection in Cambodia
Timeline
- Start
- 2023-08-07
- Primary completion
- 2026-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 30 mg | — |
| Subject | Daclatasvir | Small molecule | 60 mg | — |
| Subject | Sofosbuvir | Small molecule | 200 mg | — |
| Subject | Sofosbuvir | Small molecule | 400 mg | — |